Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immersive virtual reality simulation for technical skills acquisition in pneumothorax management and chest tube insertion: A randomized controlled trial among surgery interns.

Injury·2026
Same author

Simulation-Enhanced Learning in Nuclear Medicine: Counterpoint.

Journal of nuclear medicine technology·2026
Same author

Simulation-Enhanced Learning in Nuclear Medicine: Theory, Modalities, and Applications Across the Training Continuum.

Journal of nuclear medicine technology·2026
Same author

Simulation-Enhanced Learning in Nuclear Medicine: Practical-Use SCAFFOLD.

Journal of nuclear medicine technology·2026
Same author

From data-rich to evidence-ready: A narrative review of generative artificial intelligence as a statistical scaffold in medical radiation sciences research.

Journal of medical imaging and radiation sciences·2026
Same author

Prostate Cancer, Part 2: PSMA and Beyond.

Journal of nuclear medicine technology·2026

Related Experiment Video

Updated: Jun 2, 2026

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

Integrative oncology in Australia.

Daniel Weber1, Janelle M Wheat, Geoffrey M Currie

  • 1Faculty of Science, Charles Sturt University, Wagga Wagga, Australia. drdweber@panaxea.com

Chinese Journal of Integrative Medicine
|April 22, 2011
PubMed
Summary

Alternative medicine (AM), now complementary medicine (CM), is increasingly integrated into Western biomedicine (WB) in Australia. Medical oncology (MO) now engages in dialogue with CM practitioners, demanding evidence for cancer care integration.

More Related Videos

Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments
10:59

Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments

Published on: February 7, 2025

Clonogenic Assay: Adherent Cells
05:30

Clonogenic Assay: Adherent Cells

Published on: March 13, 2011

Related Experiment Videos

Last Updated: Jun 2, 2026

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments
10:59

Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments

Published on: February 7, 2025

Clonogenic Assay: Adherent Cells
05:30

Clonogenic Assay: Adherent Cells

Published on: March 13, 2011

Area of Science:

  • Integrative medicine
  • Complementary medicine research
  • Australian healthcare system

Background:

  • Alternative medicine (AM) has historical roots in Australia, separate from Western biomedicine (WB).
  • Over 20 years, a movement towards integrating AM, now termed complementary medicine (CM), into mainstream WB practices has emerged.
  • Integration has seen varied success, particularly within oncology.

Purpose of the Study:

  • To examine the current state of complementary medicine (CM) integration within Australian Western biomedicine (WB).
  • To highlight the specific demands for evidence-based CM within medical oncology (MO).
  • To explore the emerging dialogue and integration between MO and CM practitioners.

Main Methods:

  • Analysis of the historical context of AM/CM in Australia.
  • Review of recent trends in CM integration into WB, focusing on oncology.
  • Observation of educational advancements and public demand for integrated care.

Main Results:

  • CM is increasingly taught at the university level (PhD) in Australia.
  • Public demand is growing for medical doctors to communicate with CM practitioners.
  • Medical oncology specialists are beginning to engage in dialogue with CM counterparts.

Conclusions:

  • The integration of CM into Australian WB, especially oncology, is in its early stages.
  • High levels of evidence are required by medical oncology for CM inclusion in cancer protocols.
  • A growing openness to dialogue suggests future collaboration between WB and CM in cancer care.